Amicus Therapeutics, Inc. (FOLD) Expected to Post Earnings of -$0.32 Per Share

Wall Street analysts forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will announce earnings per share of ($0.32) for the current quarter, according to Zacks. Three analysts have provided estimates for Amicus Therapeutics’ earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.39). Amicus Therapeutics posted earnings per share of ($0.28) in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The firm is expected to announce its next earnings results on Tuesday, May 14th.

On average, analysts expect that Amicus Therapeutics will report full-year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.35) to ($0.48). For the next year, analysts anticipate that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($1.24) to ($0.49). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, February 28th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.13). Amicus Therapeutics had a negative return on equity of 54.21% and a negative net margin of 382.48%. The business had revenue of $32.64 million during the quarter, compared to the consensus estimate of $30.81 million. During the same period last year, the company earned ($0.41) earnings per share. The business’s quarterly revenue was up 121.6% compared to the same quarter last year.

A number of equities analysts have issued reports on FOLD shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 price target on shares of Amicus Therapeutics in a research note on Tuesday, February 5th. ValuEngine lowered Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Guggenheim started coverage on Amicus Therapeutics in a research note on Monday, December 17th. They set a “buy” rating and a $18.00 price target for the company. Citigroup raised Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $12.59 price target for the company in a research note on Wednesday, January 16th. Finally, BidaskClub raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 25th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Amicus Therapeutics currently has a consensus rating of “Buy” and an average price target of $18.60.

NASDAQ FOLD traded down $0.30 on Friday, reaching $13.76. 33,034 shares of the stock traded hands, compared to its average volume of 2,783,495. The company has a debt-to-equity ratio of 0.94, a quick ratio of 6.30 and a current ratio of 6.40. The firm has a market cap of $3.13 billion, a P/E ratio of -10.35 and a beta of 1.85. Amicus Therapeutics has a 12 month low of $8.27 and a 12 month high of $17.62.

In other Amicus Therapeutics news, insider Jay Barth sold 70,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $12.52, for a total transaction of $876,400.00. Following the sale, the insider now owns 156,037 shares in the company, valued at approximately $1,953,583.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $13.63, for a total transaction of $272,600.00. Following the sale, the chief executive officer now directly owns 678,290 shares of the company’s stock, valued at $9,245,092.70. The disclosure for this sale can be found here. In the last three months, insiders sold 322,769 shares of company stock valued at $3,941,371. Corporate insiders own 2.90% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of Montreal Can raised its holdings in shares of Amicus Therapeutics by 117.9% in the fourth quarter. Bank of Montreal Can now owns 3,428 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,855 shares in the last quarter. Strs Ohio raised its holdings in shares of Amicus Therapeutics by 56.0% in the fourth quarter. Strs Ohio now owns 3,900 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,400 shares in the last quarter. Sage Capital Advisors llc raised its holdings in shares of Amicus Therapeutics by 13.8% in the fourth quarter. Sage Capital Advisors llc now owns 12,400 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 1,500 shares in the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Amicus Therapeutics in the third quarter valued at about $159,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Amicus Therapeutics in the third quarter valued at about $172,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Featured Story: Short Selling Stocks, A Beginner’s Guide

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.